BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 3882831)

  • 1. Human epidermal cells and squamous carcinoma cells synthesize a cytokine that augments natural killer cell activity.
    Luger TA; Uchida A; Köck A; Colot M; Micksche M
    J Immunol; 1985 Apr; 134(4):2477-83. PubMed ID: 3882831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal cells synthesize a cytokine with interleukin 3-like properties.
    Luger TA; Wirth U; Köck A
    J Immunol; 1985 Feb; 134(2):915-9. PubMed ID: 3917479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of interleukin 1 (IL 1) in tumor-NK cell interactions: correction of defective NK cell activity in cancer patients by treating target cells with IL 1.
    Herman J; Dinarello CA; Kew MC; Rabson AR
    J Immunol; 1985 Oct; 135(4):2882-6. PubMed ID: 2993420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor.
    Uchida A; Moore M
    J Natl Cancer Inst; 1984 Dec; 73(6):1285-92. PubMed ID: 6239944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-Endorphin augments the cytolytic activity and interferon production of natural killer cells.
    Mandler RN; Biddison WE; Mandler R; Serrate SA
    J Immunol; 1986 Feb; 136(3):934-9. PubMed ID: 2934481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis.
    Sauder DN; Mounessa NL; Katz SI; Dinarello CA; Gallin JI
    J Immunol; 1984 Feb; 132(2):828-32. PubMed ID: 6361134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of rat natural killer cytotoxic factor (NKCF) produced by rat NK cell lines and the production of a murine monoclonal antibody that neutralizes NKCF.
    Ortaldo JR; Winkler-Pickett R; Morgan AC; Woodhouse C; Kantor R; Reynolds CW
    J Immunol; 1987 Nov; 139(9):3159-65. PubMed ID: 3668253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotactic properties of partially purified human epidermal cell-derived thymocyte-activating factor (ETAF) for polymorphonuclear and mononuclear cells.
    Luger TA; Charon JA; Colot M; Micksche M; Oppenheim JJ
    J Immunol; 1983 Aug; 131(2):816-20. PubMed ID: 6602848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monocyte-mediated augmentation of human natural killer cell activity: conditions, monocyte and effector cell characteristics.
    Bloom ET; Babbitt JT; Kawakami K
    J Immunol; 1986 Jul; 137(1):172-8. PubMed ID: 3711665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properties of murine and human epidermal cell-derived thymocyte-activating factor.
    Luger TA; Sztein MB; Schmidt JA; Murphy P; Grabner G; Oppenheim JJ
    Fed Proc; 1983 Jul; 42(10):2772-6. PubMed ID: 6602721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for an early calcium-independent event in the activation of the human natural killer cell cytolytic mechanism.
    Brahmi Z; Bray RA; Abrams SI
    J Immunol; 1985 Dec; 135(6):4108-13. PubMed ID: 3864859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interleukin-12 on antitumor activity of human umbilical cord blood and bone marrow cytotoxic cells.
    Condiotti R; Nagler A
    Exp Hematol; 1998 Jul; 26(7):571-9. PubMed ID: 9657131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
    Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
    J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor.
    Kasahara T; Djeu JY; Dougherty SF; Oppenheim JJ
    J Immunol; 1983 Nov; 131(5):2379-85. PubMed ID: 6195261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines.
    Kirnbauer R; Köck A; Schwarz T; Urbanski A; Krutmann J; Borth W; Damm D; Shipley G; Ansel JC; Luger TA
    J Immunol; 1989 Mar; 142(6):1922-8. PubMed ID: 2784142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of human natural killer soluble cytotoxic factors (NKCF) derived from NK-enriched lymphocyte populations: specificity of generation and killing.
    Farram E; Targan SR
    J Immunol; 1983 Mar; 130(3):1252-6. PubMed ID: 6822733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
    Frey JR; Kamber M; Peck R
    Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human keratinocytes and epidermoid carcinoma cell lines produce a cytokine with interleukin 3-like activity.
    Danner M; Luger TA
    J Invest Dermatol; 1987 Apr; 88(4):353-61. PubMed ID: 2435814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.